{"id":"W3143844999","doi":"10.1016/j.annonc.2021.03.205","title":"Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":71,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; McGill University; University of Ottawa; Regional Municipality of Durham; Juravinski Cancer Centre; Canada's Michael Smith Genome Sciences Centre; Jewish General Hospital; Kelowna General Hospital; CancerCare Manitoba; Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; University of Saskatchewan; Lakeridge Health; University of British Columbia","funders":"Canadian Institutes of Health Research; Prostate Cancer Canada; Terry Fox Research Institute; Movember Foundation; Prostate Cancer Foundation","keywords":"Cabazitaxel; Enzalutamide; Medicine; Abiraterone; Prostate cancer; Open label; Oncology; Docetaxel; Internal medicine; Phases of clinical research; Clinical trial; Chemotherapy; Cancer; Androgen deprivation therapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001359831,0.002088262,0.002718183,0.0005220877,0.0004430328,0.001082785,0.0008917124,0.001505753,0.006105242],"category_scores_gemma":[0.001756425,0.0006801102,0.001412809,0.0005628733,0.001410009,0.001086392,0.0003715928,0.003054185,0.0009758882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001051241,"about_ca_system_score_gemma":0.001416053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002872688,"about_ca_topic_score_gemma":0.007320183,"domain_scores_codex":[0.999524,0.0002428126,0.00002146306,0.00008507274,0.00004029293,0.0000864305],"domain_scores_gemma":[0.9991214,0.0002800203,0.0001643021,0.0000569647,0.00004214582,0.0003352324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.980876,0.002804175,0.0003515392,0.0004408783,0.0006037033,0.00003680888,0.0000615399,0.0004152955,0.001634426,0.00007939807,0.000671612,0.01202474],"study_design_scores_gemma":[0.9601287,0.03729825,0.001182648,0.00002443607,0.0002916687,0.00003866074,0.0000277139,0.0003225982,0.0001542834,0.0001208526,0.0003954292,0.00001477322],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892989,0.005381161,0.0004657218,0.0007325609,0.0004829172,0.001335043,0.0007624307,0.0001267852,0.001414367],"genre_scores_gemma":[0.9881403,0.003789359,0.001042909,0.0007806279,0.0003662797,0.001477797,0.000896379,0.0000310989,0.003475364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006105242,"threshold_uncertainty_score":0.02042407,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2852932482117954,"score_gpt":0.5082174511914536,"score_spread":0.2229242029796582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}